论文部分内容阅读
目的:探讨开发以核酸适体KMF2-1a为基础的乳腺癌细胞靶向阿霉素载体的可行性。方法:应用流式细胞仪检测人乳腺癌MCF-10AT1细胞对核酸适体KMF2-1a及其修饰物(药物载体)的内吞作用;将阿霉素与药物载体相互作用后,用分光光度计检测阿霉素嵌入药物载体的情况。结果:流式细胞仪检测示,核酸适体KMF2-1a及其修饰物均能被MCF-10AT1细胞特异内吞;分光光度仪检测示,阿霉素可成功嵌入至药物载体中。结论:核酸适体KMF2-1a能被MCF-10AT1细胞特异内吞,经修饰后有可能作为阿霉素的载体用于乳腺癌的靶向治疗。
OBJECTIVE: To explore the feasibility of targeting doxorubicin-containing breast cancer cells based on aptamer KMF2-1a. Methods: Endocytosis of human breast cancer cell line MCF-10AT1 was detected by flow cytometry (FCM). The interaction between doxorubicin and drug carrier was analyzed by spectrophotometer Detection of adriamycin embedded in the drug carrier situation. Results: The results of flow cytometry showed that the aptamer KMF2-1a and its modifications could be specifically endocytosed by MCF-10AT1 cells. Spectrophotometer showed that doxorubicin could be successfully inserted into the drug carrier. CONCLUSION: The aptamer KMF2-1a can be specifically endocytosed by MCF-10AT1 cells, which may be used as a carrier of doxorubicin for the targeted therapy of breast cancer.